New hope for CLL patients with weak hearts: acalabrutinib under the microscope
NCT ID NCT06651970
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have moderate to severe heart failure. Researchers want to see if acalabrutinib causes fewer heart-related side effects compared to other standard treatments. About 60 adults will take part, and the study will track heart safety and how long patients can stay on the drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- acalabrutinib (Calquence)
- What this could lead to
- If successful, this could show that acalabrutinib is a safer option for CLL patients with heart problems, reducing the risk of heart-related side effects.
- What could go wrong
- This is a small, early-phase study with only 60 participants, so results may not apply to everyone. Heart risks remain, and the drug may still cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIAC ARRHYTHMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
WITHDRAWNCharlotte, North Carolina, 28204, United States
-
Research Site
RECRUITINGColumbus, Ohio, 43210, United States
-
Research Site
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Research Site
RECRUITINGBrno, 625 00, Czechia
-
Research Site
WITHDRAWNHradec Králové, 500 05, Czechia
-
Research Site
RECRUITINGPrague, 10034, Czechia
-
Research Site
RECRUITINGCagliari, 09121, Italy
-
Research Site
RECRUITINGFlorence, 50134, Italy
-
Research Site
RECRUITINGMilan, 20122, Italy
-
Research Site
RECRUITINGMilan, 20132, Italy
-
Research Site
RECRUITINGPavia, 27100, Italy
-
Research Site
RECRUITINGPerugia, 06156, Italy
-
Research Site
RECRUITINGKrakow, 30-727, Poland
-
Research Site
RECRUITINGPoznan, 60-693, Poland
-
Research Site
RECRUITINGBarcelona, 08003, Spain
-
Research Site
RECRUITINGMadrid, 28040, Spain
-
Research Site
RECRUITINGSeville, 41009, Spain
-
Research Site
WITHDRAWNBournemouth, BH7 7DW, United Kingdom
-
Research Site
RECRUITINGOxford, OX3 7LE, United Kingdom
-
Research Site
RECRUITINGPlymouth, PL6 8DH, United Kingdom
-
Research Site
WITHDRAWNRomford, RM7 0AG, United Kingdom
-
Research Site
WITHDRAWNStockton, TS19 8PE, United Kingdom
-
Research Site
RECRUITINGSutton Coldfield, B74 3UP, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?